Press release

Study Demonstrates Improved Phototherapy Treatment Adherence by Patients Treating with the Connected Clarify Home Light Therapy System

Sponsored by Businesswire

today announced the publication of study
using the Clarify Home Light Therapy System to treat
patients with plaque psoriasis, vitiligo, and eczema. The retrospective
study demonstrated improved treatment adherence rates using the Clarify
System when compared to documented adherence to clinic-based

This was a retrospective, observational study conducted to evaluate
patients’ adherence to a prescribed 3x/week treatment protocol in a
real-world setting using the connected Clarify System. A total of 48
patient treatment records were included in the analysis: 27 with
vitiligo, 18 with psoriasis, and 3 with eczema. Ages ranged from 10 to
71 years with patients under 18 having a parent or guardian responsible
for their treatment.

Since there has been no widely adopted adherence measurement
methodology, the investigators measured treatment adherence using three
different methodologies: continuous, early, and dichotomous. These data
were compared to published adherence literature where possible. The
median patient adherence to Clarify treatment using the continuous
methodology was 80%. Using the early methodology, Clarify adherence to
treatment was 90% (compared to 68% for legacy technology). For the
dichotomous methodology, Clarify adherence was 71% (compared to 47% for
legacy technology). Using either of these adherence calculation
methodologies, these comparisons represent significant improvements in
treatment adherence when compared to documented adherence rates for
legacy technology.

“Patient adherence and compliance with accepted disease and phototherapy
treatment protocols is an important consideration to optimize outcomes
when choosing a delivery system,” said Dr. Steven R. Feldman, Professor
of Dermatology, Wake Forest School of Medicine. “The Clarify System
demonstrates improved adherence for patients treating with phototherapy
at home in real world conditions. This novel connected system provides
an exciting alternative to effectively manage the many patients with
chronic skin diseases.”

The Clarify
, cleared for commercialization by the FDA in 2017, is
indicated for localized phototherapeutic treatment of dermatologic
conditions such as psoriasis, vitiligo, atopic dermatitis (eczema),
seborrheic dermatitis and leukoderma on all skin types (I-VI). It is the
first and only connected phototherapy system that uses an app on the
patient’s own smartphone (iOS or Android) to manage the dose, frequency,
and duration of UVB light therapy, helping to ensure that patients
receive the proper doses recommended by the American Academy of
Dermatology in its published Guidelines of Care for the Management of
Psoriasis and Psoriatic Arthritis
and The Vitiligo Working Group
Recommendations for NarrowBand Ultraviolet B Light Phototherapy
Treatment of Vitiligo
. The treatment regimen is prescribed by the
patient’s physician but monitored and controlled by the Clarify System,
enabling patients to administer treatment with clinical precision in the
convenience of their homes. The connected system monitors dosing,
adherence, compliance, patient progress and satisfaction.

The Clarify smartphone app syncs to a patented, lightweight, handheld
device which guides patients through delivering targeted narrowband UVB
phototherapy treatments for their specific skin conditions. All
treatment records, including photographs
and patient-reported outcomes, are available to both the patient and the
physician and can be used for evaluation during follow-up visits.
Clarify CarePartners, trained patient support personnel, act as the
first line of support for patients – coaching them on the use of the
system and encouraging treatment adherence – greatly reducing the burden
of these functions on the physician’s practice.

“NB-UVB phototherapy is one of the most cost-effective treatments
available for patients with chronic skin conditions, as long as
treatment protocols are followed,” said George Mahaffey, President & CEO
of Clarify Medical. “This study shows that the Clarify System’s
integrated smartphone-based treatment scheduling, reminders, and
improved usability, combined with our CarePartner Support, helps
patients adhere to their personalized home phototherapy treatment
protocols as prescribed by their physicians. The Clarify System monitors
patient adherence and compliance in real time which now, for the first
time, provides visibility to all stakeholders – patients, physicians,
and insurance providers. We expect this will greatly improve outcomes.”

Clarify Medical is a private San Diego-based medical device company
focused on developing innovative technology, products and services that
improve care for people with chronic skin conditions. Its Clarify Home
Light Therapy System is now available nationally in the US. Learn more